LUPUS RESEARCH ALLIANCE INC

Financials

From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.

Officers, directors and key employees

As listed on the 990 for the year ended December 31, 2025, highest compensation first.

Address and contacts

Address (IRS master file)

52 VANDERBILT AVE RM 401, NEW YORK, NY 10017-3851

Principal officer (990 for 2025)

DEBRA ROSE, 52 VANDERBILT AVE SUITE 401, NEW YORK, NY 10017

Signed the 990

DEBRA ROSE, CHIEF FINANCIAL OFFICER

Phone

(646) 884-6000

Website

LUPUSRESEARCH.ORG

Return prepared by

LUTZ AND CARR CPAS LLP

Mission

PUTTING PEOPLE WITH LUPUS AT THE CENTER OF ALL WE DO, THE LUPUS RESEARCH ALLIANCE DRIVES THE DISCOVERY & DEVELOPMENT OF NEXT GENERATION LUPUS DIAGNOSTICS AND CURATIVE TREATMENTS THROUGH INNOVATIVE RESEARCH & COLLABORATIONS.

Program accomplishments

• THE LUPUS RESEARCH ALLIANCE (LRA), THE LARGEST NON-GOVERNMENTAL, PRIVATE FUNDER OF LUPUS RESEARCH WORLDWIDE. THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD INCLUDES TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE LRA'S BOARD OF DIRECTORS, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA. THE LRA FUNDS INNOVATIVE RESEARCH THAT SPANS THE SPECTRUM FROM FOUNDATIONAL TO CLINICAL RESEARCH. THE LRA HAS INVESTED NEARLY $228 MILLION IN LUPUS RESEARCH GRANTS INCLUDING 675+ RESEARCH GRANTS. IN 2025 OVER $12 MILLION WAS AWARDED IN GRANTS FOR OVER 31 HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE. BELOW IS A SUMMARY OF RESEARCH GRANTS AND PROGRAMS FUNDED BY THE LRA IN 2025: 6 LUPUS INNOVATION AWARD GRANTS WERE AWARDED TOTALING OVER $2 MILLION OVER TWO YEARS, THIS PROGRAM SUPPORTS PIONEERING, HIGH-RISK, HIGH-REWARD PROJECTS ADDRESSING MAJOR CHALLENGES IN LUPUS RESEARCH. EARLY-STAGE INVESTIGATORS ARE GIVEN SPECIAL CONSIDERATION DURING THE REVIEW PROCESS AND ARE ELIGIBLE FOR A THIRD YEAR OF FUNDING; 7 EMPOWERING LUPUS RESEARCH ADMINISTRATIVE SUPPLEMENT GRANTS WERE AWARDED TOTALING $180,000. THIS PROGRAM SUPPORTS PROMISING TRAINEES WHO ARE WORKING WITH LRA-FUNDED RESEARCHERS OR INVESTIGATORS FOCUSED ON AUTOIMMUNITY SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH, DEPARTMENT OF DEFENSE, OR EQUIVALENT GRANTS IN GOOD STANDING.2 MECHANISTIC CLINICAL AWARDS WERE AWARDED TOTALING ALMOST $1.5 MILLION TO DEEPEN OUR EXPLORATION OF LIFESTYLE INTERVENTIONS IN A NIMBLER CLINICAL TESTING FRAMEWORK. THE AWARD PROVIDES FUNDS FOR PILOT STUDIES TESTING LIFESTYLE INTERVENTIONS IN CONCERT WITH HYPOTHESIS-DRIVEN MECHANISTIC ANALYSIS TO ILLUMINATE THE UNDERLYING EFFECTS OF LUPUS.2 GLOBAL TEAM SCIENCE AWARDS (GTSA) TOTALING ALMOST $6 MILLION TO SUPPORT INTERDISCIPLINARY, COLLABORATIVE, AND HIGHLY SYNERGISTIC PROJECTS THAT FOCUS ON THE MOLECULAR UNDERSTANDING OF HUMAN LUPUS AND THE HETEROGENEITY OF THE DISEASE. THESE AWARDS ALSO INCLUDE PLANNING GRANTS THAT SUPPORT RESEARCHERS IN PREPARING COMPETITIVE FULL APPLICATIONS.1 CROSS COLLABORATIVE GTSA SUPPLEMENT FOR 230K TO ENCOURAGE FURTHER SYNERGIES AND FOSTER THE CROSS-POLLINATION OF IDEAS ACROSS FUNDED GTSA TEAMS. BY MAXIMIZING THE POTENTIAL WITHIN THE GTSA PROGRAM, THE LRA AIMS TO PUSH THE BOUNDARIES OF PATIENT-CENTRIC RESEARCH, GENERATING COLLECTIVE KNOWLEDGE ON DISEASE HETEROGENEITY AND LEADING TO INNOVATIVE APPROACHES TO THERAPEUTIC TREATMENTS AND DISCOVERIES THAT WILL SHAPE THE FUTURE OF LUPUS RESEARCH AND CLINICAL TRANSLATION. 4 EMPOWERING LUPUS RESEARCH CAREER DEVELOPMENT AWARDS TOTALING $1.8 MILLION SUPPORTING OUTSTANDING EARLY-CAREER SCIENTISTS WHO REFLECT THE COMMUNITIES AND POPULATIONS OF PEOPLE LIVING WITH LUPUS. THIS AWARD PROVIDES FUNDS FOR AWARDEES TO ESTABLISH A COMPETITIVE INDEPENDENT RESEARCH PROGRAM IN THE LUPUS RESEARCH COMMUNITY.1 EMPOWERING LUPUS RESEARCH POSTDOCTORAL AWARD FOR $200K TO SUPPORT PROMISING SCIENTIST WHO REFLECTS THE COMMUNITIES AND POPULATIONS OF PEOPLE LIVING WITH LUPUS. THE AWARD PROVIDES SUPPORT FOR AWARDEES TO GENERATE THE SCIENTIFIC DATA AND UNIQUE RESEARCH IDEAS NECESSARY TO ULTIMATELY TRANSITION TO AN INDEPENDENT LUPUS RESEARCHER ROLE.IN ADDITION TO ITS TRADITIONAL GRANTS, THE LRA AWARDED THE LUPUS INSIGHT PRIZE, A $100,000 AWARD THAT RECOGNIZES A LEADING RESEARCHER WHO HAS MADE A MAJOR CONTRIBUTION RELEVANT TO LUPUS. THE PRIZE RECOGNIZES AND HONORS SIGNIFICANT SCIENTIFIC INSIGHTS THAT ADVANCE UNDERSTANDING OF THE CAUSES, PATHOGENESIS, OR TREATMENT OF LUPUS.AS PART OF ITS COMMITMENT TO COLLABORATION, THE LRA CONTINUED IN 2025 TO WORK WITH PARTNERS ACROSS SECTORS TO ACCELERATE RESEARCH DISCOVERIES, LEVERAGE RESOURCES, AND EXPEDITE THE DRUG DEVELOPMENT PROCESS. BY BRINGING TOGETHER KEY CONTRIBUTORS IN THE FIGHT AGAINST LUPUS--INCLUDING GRANTEES, SCIENTIFIC ADVISORS, CLINICIANS, THE BIOPHARMACEUTICAL INDUSTRY, THE U.S. GOVERNMENT, AND PEOPLE LIVING WITH LUPUS--THE LRA AIMS TO IMPROVE QUALITY OF LIFE FOR THOSE AFFECTED BY THE DISEASE.THE LRA'S ROBUST FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS DESIGNED TO IMPROVE THE LIVES OF PEOPLE WITH LUPUS. THROUGH A COMPETITIVE PEER-REVIEW PROCESS, THE LRA SUPPORTS PROJECTS THAT AIM TO TRANSLATE RESEARCH FINDINGS FROM THE BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE.
  Expenses $15,426,770 · grants $12,958,702
• THE LUPUS RESEARCH ALLIANCE (LRA) ADVANCED ITS SCIENTIFIC MISSION IN 2025 BY STRENGTHENING ITS RESEARCH STRATEGY, EXPANDING OPERATIONAL GRANTMAKING ACTIVITIES, AND ADVANCING COLLABORATIVE INITIATIVES DESIGNED TO ACCELERATE PROGRESS IN LUPUS DIAGNOSIS, TREATMENT, AND CLINICAL TRIAL READINESS.IN 2025, LRA IMPLEMENTED THE SECOND YEAR OF ITS 2024-2028 RESEARCH STRATEGY. AS PART OF THIS WORK, LRA RENEWED THE COMMON MECHANISMS IN AUTOIMMUNE DISEASES PROGRAM AND ADVANCED PLANNING FOR BIOMARKER AND DATA STRATEGIES INTENDED TO SUPPORT MORE PRECISE, EFFICIENT, AND COLLABORATIVE LUPUS RESEARCH.LRA'S GRANTMAKING PROGRAMS, INCLUDING THE GLOBAL TEAM SCIENCE AWARD, EMPOWERING RESEARCH PROGRAM, LUPUS INNOVATION AWARD, TRANSLATIONAL BRIDGE AWARD, AND MECHANISTIC CLINICAL TRIAL AWARD, CONTINUED TO SUPPORT INNOVATIVE AND TRANSLATIONAL LUPUS RESEARCH. DURING 2025, LRA ALSO RELEASED MULTIPLE REQUESTS FOR APPLICATIONS THROUGH THE GLOBAL TEAM SCIENCE AWARD AND CONTINUED THE ADMINISTRATIVE SUPPLEMENT TRAINING PROGRAM TO HELP STRENGTHEN THE LUPUS RESEARCH WORKFORCE. TO INCREASE AWARENESS OF ITS SCIENTIFIC PROGRAMS AND RESEARCH FINDINGS, LRA PRESENTED WORK AT MAJOR SCIENTIFIC MEETINGS AND CONVENED ITS ANNUAL FORUM FOR DISCOVERY AND ADDITIONAL PROGRAM-SPECIFIC INVESTIGATOR MEETINGS.OPERATIONAL IMPROVEMENTS INCLUDED THE SELECTION AND IMPLEMENTATION OF A NEW GRANT MANAGEMENT SYSTEM, THE RECRUITMENT AND ONBOARDING OF STAFF MEMBERS INCLUDING ADMINISTRATORS AND SCIENTISTS AND CONTINUING THE STRENGTHENING OF THE RESEARCH TEAM THROUGH TARGETED TEAM-BUILDING AND PROFESSIONAL DEVELOPMENT EFFORTS. LUPUS ABC HAS BEEN SUCCESSFULLY ESTABLISHED AS A MODEL PUBLIC-PRIVATE PARTNERSHIP IN THE REGULATORY SPACE, DEMONSTRATING LEADERSHIP AND INNOVATION IN ADVANCING LUPUS THERAPY DEVELOPMENT. SINCE ITS LAUNCH, PARTICIPATION IN LUPUS ABC, INCLUDING ENGAGEMENT FROM THE FDA, HAS GROWN THREEFOLD, HIGHLIGHTING THE CONSORTIUM'S CONVENING POWER AND COLLABORATIVE INFLUENCE. WORKS FROM LUPUS ABC HAS RESULTED IN FIVE PUBLICATIONS, INCLUDING ONE WITH THE FDA'S ACKNOWLEDGMENT OF CLASI 70 AS A PRIMARY EFFICACY ENDPOINT IN CUTANEOUS LUPUS CLINICAL TRIALS, MARKING A SIGNIFICANT ADVANCEMENT IN CLINICAL OUTCOME MEASUREMENT. IN ADDITION, LUPUS ABC LAUNCHED THREE NEW WORKING GROUPS, TWO OF WHICH FOCUS ON PATIENT-REPORTED OUTCOMES (PRO) TO FURTHER INTEGRATE PATIENT PERSPECTIVES INTO RESEARCH AND REGULATORY STRATEGIES. THE THIRD WORKING GROUP CENTERS ON IMMUNE RESET THERAPIES, A RAPIDLY EVOLVING FIELD WITH PROMISING POTENTIAL FOR INDIVIDUALS WITH LUPUS. IN 2025, LUPUS ABC RELEASED ITS FIRST REQUEST FOR PROPOSALS (RFP) WITH NEW PROJECTS SELECTED FOR SUPPORT TO BE ANNOUNCED IN MID-2026.LUPUS NEXUS COMPLETED ITS INFRASTRUCTURE BUILD AND OFFICIALLY LAUNCHED TO BOTH RESEARCH AND PATIENT COMMUNITIES. IT FINALIZED FOUNDATIONAL ANALYSIS PLANS, SELECTED KEY VENDORS, AND RECRUITED 635 PARTICIPANTS. ADDITIONALLY, 7 NEW CLINICAL SITES WERE ACTIVATED THROUGH LUCIN (SEE BELOW), AND A SUSTAINABLE FINANCIAL MODEL WITH A DEFINED MEMBERSHIP FEE STRUCTURE WAS ESTABLISHED. THE PROGRAM WAS PRESENTED AT 8 SCIENTIFIC CONFERENCES, HELPING TO SPREAD THE WORD ABOUT THE RESOURCE AVAILABLE TO THE RESEARCH COMMUNITY.LUPUS THERAPEUTICS,LLC:THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018. WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 60+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.4 MILLION IN GRANTS IN 2025 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 250+ LUCIN PROVIDERS AND THE LRA TO SUPPORT ACADEMIC, NONPROFIT AND BIOTECH AND PHARMACEUTICAL ORGANIZATIONS TO PLAN, INITIATE AND MANAGE CLINICAL RESEARCH. THIS OCCURS THROUGH DIVERSE ADVISORY SERVICES AND DIRECT CLINICAL OPERATIONS SUPPORT. AN ANNUAL LUCIN COMMUNITY MEETING IS HELD TO BRING TOGETHER ALL THE PARTNERS IN CLINICAL RESEARCH TO HIGHLIGHT RECENT ADVANCEMENTS, BOLSTER UNDERSTANDING, ADDRESS CURRENT CHALLENGES IN CLINICAL RESEARCH AND ENCOURAGE COLLABORATION FOR SUCCESSFUL DEVELOPMENT OF NEW TREATMENT APPROACHES.IN ADDITION, LT HAS EXPANDED THE FIRST PEER-TO-PEER CLINICAL TRIALS EDUCATION PROGRAM, PATIENT ADVOCATES FOR LUPUS STUDIES OR PALS TO INCLUDE TRIAL BUDDY SUPPORT DURING PARTICIPATION IN CLINICAL TRIALS. PALS AIMS TO IMPROVE CLINICAL RESEARCH AWARENESS, KNOWLEDGE AND ENROLLMENT, WITH A SPECIFIC FOCUS ON MAKING SURE POPULATIONS AT GREATEST RISK FOR LUPUS ARE WELL REPRESENTED IN STUDIES. LT ALSO SUPPORTS OTHER PATIENT ENGAGEMENT ACTIVITIES SUCH AS PATIENT ADVISORY BOARDS, PATIENT VISITS AND PATIENT PROTOCOL REVIEW COMMITTEES TO ENSURE THAT INDIVIDUALS IMPACTED BY LUPUS HAVE A VOICE IN THE TREATMENT DEVELOPMENT PROCESS. FINALLY, LT EFFORTS SUPPORT VARIOUS EDUCATION OFFERINGS FOR PROVIDERS AND PATIENTS, AND COMMUNITY-BASED OUTREACH TO ENSURE REPRESENTATIVE PARTICIPATION OF THE ENTIRE LUPUS COMMUNITY IN CLINICAL RESEARCH.
  Expenses $17,084,288 · grants $3,052,329 · revenue $2,057,382
• THE LUPUS RESEARCH ALLIANCE (LRA)'S ADVOCACY EFFORTS FOCUS ON EDUCATING CONGRESS ABOUT LUPUS AND URGING CONGRESS AND THE ADMINISTRATION TO PROVIDE THE FUNDS AND SUPPORT NEEDED TO ADVANCE LUPUS RESEARCH THAT CAN LEAD TO BETTER TREATMENTS AND, ULTIMATELY, A CURE. THE TOP GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM FOCUS MAINLY ON FUNDING FOR LUPUS RESEARCH THAT WILL LEAD TO BETTER TREATMENTS FOR PEOPLE LIVING WITH LUPUS. GOALS INCLUDE: INCREASING FEDERAL FUNDING FOR LUPUS RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH), AND SPECIFICALLY THE NATIONAL INSTITUTE FOR ALLERGY & INFECTIOUS DISEASE (NIAID), AND THE NATIONAL INSTITUTE FOR ARTHRITIS & MUSCULOSKELETAL DISORDERS (NIAMS). ADDITIONALLY, THE LRA ADVOCATES FOR LUPUS RESEARCH THROUGH THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP); SUPPORTING THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC), THE LRA'S PARTNERSHIP WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA); AND ENSURING THE PATIENT VOICE IS INCORPORATED IN THE DRUG DEVELOPMENT PROCESS. VOLUNTEER ADVOCATES ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LRA'S ONGOING PUBLIC POLICY PROGRAM EFFORTS, CONGRESS HAS APPROPRIATED $75 MILLION FOR THE CDMRP LUPUS RESEARCH PROGRAM OPERATED BY THE ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND. GIVEN THE HIGH DEMAND FOR NEW RESEARCH ALONGSIDE THE RISING NUMBERS OF WOMEN TREATED AT MILITARY HEALTH FACILITIES, AS WELL AS THE LINK BETWEEN POST-TRAUMATIC STRESS DISORDER (PTSD) AND THE DEVELOPMENT OF AN AUTOIMMUNE DISEASE, THE LUPUS RESEARCH ALLIANCE HAS WORKED TO CONVINCE CONGRESS TO INCREASE ITS INVESTMENT AND PROVIDE $15 MILLION FOR THE LUPUS RESEARCH PROGRAM IN THE DEFENSE APPROPRIATIONS BILL. THIS ADDITIONAL INVESTMENT IS CRITICAL FOR DISCOVERIES THAT CAN MAKE A DIFFERENCE IN PATIENTS' ABILITY TO BE THE BEST VERSION OF THEMSELVES. THE LRA LED THE PUSH FOR THE CREATION OF THE LUPUS RESEARCH PROGRAM, WHICH WAS FIRST FUNDED WITH $5 MILLION IN 2017 AND INCREASED TO $10 MILLION PER YEAR IN 2020. IN 2025, THE FUNDING FOR THIS PROGRAM WAS NOT ALLOCATED IN THE BUDGET, LEADING THE LUPUS RESEARCH ALLIANCE TO PUSH FOR THIS FUNDING TO BE RESTORED IN THE FY26 BUDGET. LRA LEADERSHIP, ADVOCATES, AND ALLIED MEMBERS OF CONGRESS ARE WORKING TO ADVANCE RESEARCH PRIORITIES LIKE THIS THAT ARE CRITICAL TO THE LUPUS RESEARCH ALLIANCE AND ALL PEOPLE IMPACTED BY LUPUS. IN 2025, THE LRA CONTINUED WORK TO STAVE OFF PROPOSED CUTS TO MEDICAL RESEARCH AT THE NIH FOR LUPUS AND ALL DISEASES. LRA STAFF, LEADERSHIP, AND ADVOCATES ENGAGED IN MEETINGS WITH MEMBERS OF CONGRESS AND CONGRESSIONAL STAFF IN-PERSON, BY PHONE, AND THROUGH VIRTUAL MEETINGS, AND LRA ORGANIZED A CONGRESSIONAL BRIEFING IN COORDINATION WITH THE LEADERS OF THE BIPARTISAN CONGRESSIONAL LUPUS CAUCUS. TO SUPPORT THESE EFFORTS, THE LRA CREATED WRITTEN RESOURCES AND HELD VIRTUAL OFFICE HOUR SESSIONS TO ANSWER QUESTIONS, AND HELP ADVOCATES PREPARE TO SHARE THEIR STORIES AND EMPHASIZE THE IMPORTANCE OF RESEARCH FUNDING. ONGOING ADVOCACY FOCUSES ON ENACTING LEGISLATION THAT INCLUDES THE FEDERAL FUNDING NECESSARY TO SUPPORT INVESTIGATORS AND FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE THE UNDERSTANDING OF AND TREATMENT FOR LUPUS.
  Expenses $645,427 · grants $40,305

What it must file and when

IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.

IRS record

EIN

58-2492929

Tax-exempt status

501(c)(3): Charitable, religious, educational or scientific organization

Foundation status

Publicly supported organization (170(b)(1)(A)(vi))

Donations deductible (Pub 78)

Public charity, 50% deduction limit

Exempt since

2000

Accounting year ends

December

Files

Form 990 or 990-EZ

Category (NTEE)

Medical research (H11)

Assets (IRS master file)

$88,318,156

Income (IRS master file)

$42,977,371

Filing history

990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 58-2492929).

Questions about LUPUS RESEARCH ALLIANCE INC

What is the EIN of LUPUS RESEARCH ALLIANCE INC?

The employer identification number (EIN) of LUPUS RESEARCH ALLIANCE INC is 58-2492929.

Is LUPUS RESEARCH ALLIANCE INC tax-exempt?

Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2000.

Are donations to LUPUS RESEARCH ALLIANCE INC tax-deductible?

Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).

Which annual return does LUPUS RESEARCH ALLIANCE INC file?

Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.

When is the next return of LUPUS RESEARCH ALLIANCE INC due?

The return for tax year 2026 (the year ending December 31, 2026) is due May 17, 2027. Form 8868 extends it by six months; the 990-N cannot be extended.

When did LUPUS RESEARCH ALLIANCE INC last file with the IRS?

The latest return in the IRS public files is the 990 for the year ended December 2025.

Who is the principal officer of LUPUS RESEARCH ALLIANCE INC?

The 990 for the year ended December 31, 2025 names DEBRA ROSE.

Who are the officers and directors of LUPUS RESEARCH ALLIANCE INC?

The 990 for the year ended December 31, 2025 lists 38 people; 15 received compensation from the organization, the highest $457,769 (ALBERT T ROY, CEO AND PRESIDENT).

How much revenue does LUPUS RESEARCH ALLIANCE INC have?

On its 990 for the year ended December 31, 2025 it reported revenue of $23,701,449, expenses of $42,149,930 and total assets of $88,318,156 at year end.

Other nonprofits in NEW YORK

• MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH
  EIN 13-4141945 · last filed 990 for 2025
• PUBLIC HEALTH SOLUTIONS
  EIN 13-5669201 · last filed 990 for 2025
• PARKINSONS FOUNDATION INC
  EIN 13-1866796 · last filed 990 for 2025
• LICR FUND INC
  EIN 13-3573053 · last filed 990 for 2024
• CARDIOVASCULAR RESEARCH FOUNDATION
  EIN 52-1752653 · last filed 990 for 2024
• GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC
  EIN 13-4128413 · last filed 990 for 2024
• INTERNATIONAL BRAIN RESEARCH ORGANIZATION
  EIN 88-4372025 · last filed 990 for 2024
• CANCER RESEARCH INSTITUTE INC
  EIN 13-1837442 · last filed 990 for 2025

All nonprofits in NEW YORK · New York · Medical research